Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Acquisition strengthens Aspire Pharma’s strategic portfolio
Acquisition strengthens Aspire Pharma’s strategic portfolio
Read also
FDA approves Roche’s Gazyva for lupus nephritis
The US Food and Drug Administration (FDA) has granted approval for Roche’s Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are on...
iBio to Present New Preclinical Data
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
FDA approves Glaukos’ Epioxa
FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment
Liberate Bio’s CAR-M
CAR-M cell therapy shows promise in preclinical studies
